GENETIC TOXICOLOGY SCREENING: A COVANCE PERSPECTIVE

Robert Smith Covance Labs 3rd October 2018



Navigating drug discovery and development



3-6 years

6-7 years

0.5-2 years



2 Genetic Toxicology Screening October 2018

Genetic Toxicology Screening: Rationale for Early Evaluation

Screening allows early identification of potential genotoxicity

- Focus time and resource on most promising compounds
- Efficient planning for follow-up testing
- Reduces 'surprises' in later development
- Advantages of screening assays
 - Reduced test article requirement (miniaturised designs)
 - Quicker turn-around time
 - Lower cost compared to regulatory assays
 - Predictive of regulatory tests
- One approach is to mimic the regulatory study as closely as possible for best predictivity
 - Design dependent on test article availability





CRO Perspective

- Historically, only GLP and Pre-GLP studies were outsourced to CRO
 - Early screening with mg of compound performed in-house
- Industry has moved towards outsourcing earlier in development
- ► This has created challenges and opportunities
 - Miniaturisation of regulatory assays with minimal compound (to predict GLP assay outcome)
 - Turn around times (TATs) for multiple clients
 - Client specific requirements (try to mimic in-house design/strategy)
- Streamlined process to provide high quality data with reduced TATs



Genetic Toxicology Screening Assays

- Most regulatory genetic tox assays can be scaled down for screening (to conserve test article, time, etc.)
- Screening should ideally cover gene mutation and chromosome damage
 - Bacterial Mutation Assay (Ames)
 - In vitro micronucleus
- Different designs based on availability of test article







Ames Screen: Abbreviated and Multi-Well Modifications

	a	a 	a							
Format	Standard	6-Well	24-Well							
Area	~500 mm ²	~90 mm ²	~20 mm ²							
Maximum concentration	5000 µg/plate	1000 µg/well*	250 µg/well*							
Compound per strain	40 to 50 mg per strain	15 mg per strain	3 mg per strain							
*Equivalent to 5000 μg/plate										

► Strains TA98 and TA100 minimum screen



Ames: Standard v Multi-Well Screens Historical Vehicle Control Data

- Ranges comparable between standard and multi-well
 - increased variability with multi-well assay (low revertant numbers)
- Recommendations/Considerations with low spontaneous revertant strains
 - Use strain TA97a in place of TA1537
 - Use strain WP2 uvrA pKM101 for *E.coli* strain
 - Use historical data to help assess biological relevance of small increases (e.g. strains TA98 and TA1535)

	Revertant Numbers										
	Mean Reverta	ants per Plate	99% Reference Range								
Strain	Standard Ames	24-Well Ames	Standard Ames	24-Well Ame							
TA98	24	2	10 to 46	0 to 7							
	34	3	15 to 56	0 to 11							
TA100	113	7	76 to 170	1 to 15							
	123	7	81 to 157	0 to 15							
TA1535	22	2	7 to 45	0 to 7							
	18	1	9 to 34	0 to 4							
TA1537	10	1	2 to 25	0 to 3							
	18	1	7 to 30	0 to 4							
TA97a	113 8		74 to 155	1 to 19							
	184	10	105 to 249	3 to 19							
TA102	270	25	185 to 362	15 to 40							
	269	29	179 to 393	11 to 45							
WP2 uvrA	171	15	121 to 241	7 to 25							
pKM101	219	20	148 to 303	11 to 32							



Ames: Standard v Multi-Well Screens Positive/Negative Comparison

	Evenented	Act	ual Outco	Comparison			
Validation Compounds	Outcome	24-well plate	90-mm plate	6-well plate	24-well vs 90-mm	6-well vs 90-mm	
2-Aminoanthracene	+	+	+	+	 Image: A second s	\checkmark	
Anthracene	_	-	_	_	 Image: A second s	\checkmark	
ICR-191	+	+	+	+	 Image: A set of the set of the	 Image: A second s	
Benzo[a]pyrene	+	+	+	+	 Image: A second s	\checkmark	
Sodium azide	+	+	+	+	 Image: A set of the set of the	\checkmark	
4-Methoxycarbonyl-phenylboronic acid	Unknown	I	-	Ι	 Image: A set of the set of the	\checkmark	
1-H-Pyrazole-4-boronic acid	Unknown	+	+	+	 Image: A set of the set of the	\checkmark	
4-Nitroquinoline	+	+	+	+	 Image: A second s	\checkmark	
2-Nitrofluorine	+	+	+	+	 Image: A second s	\checkmark	
7,12-Dimethylbenzanthracene	+	+	+	+	 Image: A second s	\checkmark	
L-Methionine	_	-	_	-	\checkmark	\checkmark	

The 24- and 6-well format Ames assay correctly predicts the overall outcome in the standard 90-mm plate Ames assay

 Multi-well formats correctly predict overall outcome from standard Ames assay



Ames: Standard v Multi-Well Screens 24-Well v 90 mm Plates

	TA	97a	T/	498	TA	100	TA	1535	WP2	2uvrA	WP2 pKM	uvrA 1101	TA	97a	T/	498	TA	100	0 TA1535 WP2uvrA		uvrA	WP2 pKM	uvrA A101	
	No S9	+ \$9	No S9	+ \$9	No S9	+ \$9	No S9	+ \$9	No S9	+ \$9	No S9	+ \$9	No S9	+ \$9	No S9	+ \$9	No S9	+ \$9	No S9	+ \$9	No S9	+ \$9	No S9	+ \$9
					2-4	Aminoa	nthrac	ene									1-H-Pyi	azole-	4-boroi	nic aci	d			
24-well plate assay	+	+	-	+	-	+	-	+	_	+	-	+	-	-	-	-	-	—	-	-	-	—	-	—
90-mm plate assay	+	+	+	+	+	+	_	+	_	+	-	+	—	—	_	—	_	—	+	+	+	+	_	—
24-well vs 90-mm plates	× -	 Image: A second s	×	 Image: A second s	×	 Image: A second s	 Image: A second s	×	× -	× -	× .	× -	× -	× -	× -	~	× -	× -	×	×	×	×	 Image: A second s	1
						Anthr	acene										4	-Nitroq	juinolin	ie				
24-well plate assay	-	-	-	-	-	-	_	—	_	-	-	-	+	-	+	-	+	—	-	—	-	—	+	—
90-mm plate assay	-	-	_	-	-	_	_	-	_	-	-	—	+	-	+	_	+	+	+	—	+	+	+	—
24-well vs 90-mm plates	 Image: A second s	 ✓ 	×	√	1	√	× -	×	× .	1	×	× -	× -	√	1	√	~	×	×	~	×	×	 ✓ 	1
						ICR	-191										:	2-Nitro	fluorine	9				
24-well plate assay	+	+	+	-	+	-	-	—	-	-	-	—	+	+	+	+	+	+	—	—	—	—	-	—
90-mm plate assay	+	+	+	_	+	—	—	_	_	_	+	_	+	+	+	+	+	+	—	_	_	_	_	_
24-well vs 90-mm plates	× -	 Image: A second s	×	 Image: A second s	× -	 Image: A second s	 Image: A second s	×	× .	× -	×	× -	× -	× -	 Image: A second s	 ✓ 	× -	× -	× -	× -	× -	× -	 ✓ 	1
					E	Benzo[a	a]pyren	ie					7,12-Dimethylbenzanthracene											
24-well plate assay	—	+	—	+	—	+	-	-	—	-	—	—	—	+	—	+	—	+	-	—	—	—	+	—
90-mm plate assay	—	+	—	+	—	+	-	-	—	-	-	-	+	+	-	+	—	+	-	-	—	—	-	+
24-well vs 90-mm plates	× -	 ✓ 	 ✓ 	 Image: A second s	 ✓ 	 ✓ 	 ✓ 	1	1	1	 ✓ 	 Image: A second s	ж	 ✓ 	 ✓ 	 ✓ 	 ✓ 	× -	 ✓ 	× -	1	×	×	×
						Sodiu	n azide	è										L-Meth	nionine					
24-well plate assay	—	-	-	-	+	-	+	-	-	-	-	-	- 1	-	-	-	-	—	-	-	—	_	-	—
90-mm plate assay	—	-	—	-	+	—	+	+	—	-	—	-	—	-	-	—	—	—	-	-	—	—	-	—
24-well vs 90-mm plates	 ✓ 	 Image: A second s	 ✓ 	 Image: A second s	 Image: A second s	 ✓ 	 Image: A second s	×	 ✓ 	 ✓ 	 Image: A second s	 Image: A second s	× -	 ✓ 	 Image: A second s	 ✓ 	 ✓ 	 Image: A second s	 Image: A second s	 Image: A second s	~	 Image: A second s	 Image: A second s	 Image: A second s
				4-Met	hoxyca	rbonyl	pheny	lboron	ic acid															
24-well plate assay	—	-	—	_	+	—	_	—	—	—	-	_												
90-mm plate assay	—	-	_	_	-	-	_	_	_	_	-	_												
24-well vs 90-mm plates	 Image: A second s	 Image: A second s	1	1	×	1	1	1	1	1	 ✓ 	1												

Good concordance between strains (multi-well v standard Ames)



Ames: Standard v Multi-Well Screens Concentration by Concentration

Good concordance between concentrations





Negative

Positive

Ames Screens: Standard v Multi-Well Concentration by Concentration

Without metabolic activation 90-mm plates TA97a **TA98** TA100 TA1535 WP2uvrA WP2uvrA pKM101 With metabolic activation TA97a **TA98** TA100 TA1535 WP2uvrA WP2uvrA pKM101

90-mm vs 24-Well Plates, ICR-191

 Corresponding concentrations show good concordance (multi-well v standard Ames)



11 Genetic Toxicology Screening October 2018

Ames Screens: Pros / Cons

- Multi-Well modifications generally show good concordance to the standard plate assay
 - Outcome (positive / negative)
 - Concentration
- Current OECD initiative: Can mini-Ames formats be used as surrogate for Ames assay in certain circumstances?
- Can use the same strains
- Significantly less test article usage
- Target follow-up testing in specific strains to investigate equivocal results (increase replicate wells or in full plate)
- Considerations with low spontaneous revertant strains
 - Use appropriate strains
 - Use of historical ranges aids interpretation





In Vitro MN Screens: Abbreviated and 96-Well Formats

		a	
Format	Tube	96-Well	
Volume	5 / 10 mL	150 µL	
Maximum concentration	1 mM / 50 Cytotoxicity limit	00 μg/mL for MN analysis	
Compound	50 to 200 mg	5 mg	
Cells	Human PBLs or TK6, Mouse L5178	TK6	

 Extended treatment, -S-9 & Short treatment +S-9 minimum

- ► Reduced BN cells (500 to 1000 per concentration)
- Semi-automated MN analysis using Metafer
- Same cytotoxicity measures
- Other volumes and cell lines can be used

In Vitro MN: Standard v 96-Well Historical vehicle controls

	MNBN Cell Frequency (%)												
	3+27 Hour +S9 Standard TK6	(with Cyto B) Micro TK6	27+27 Hour -S9 (with Cyto B) Standard TK6 Micro TK6										
Mean	0.60	0.69	0.68	0.82									
Observed Range	0.10 to 1.30	0 to 1.40	0.30 to 2.10	0 to 2.00									
95% Reference Range	0.12 to 1.20	0.02 to 1.29	0.36 to 1.78	0.20 to 1.81									

Historical ranges comparable (96-well v standard tube format)



In Vitro MN: Standard v 96-Well Positive / Negative Comparison

Test Chemical	Expected Outcome	96-Well w/ Cyto-B	96-Well micro TK6 w/ Cyto-B w/o Cyto-B w/ Cyto-B w/o Cyto-B					
Saline	-	_	_	_	_	\checkmark		
Cyclophoshamide (CPA)	+	+	+	+	+	✓		
Benzo(a)pyrene	+	+	+	+	+	\checkmark		
Mitomycin C (MMC)	+	+	+	+	+	\checkmark		
Vinblastine (VIN)	+	+	+	+	+	\checkmark		
Noscapine (NOS)	+	+	+	+	+	\checkmark		
Colchicine	+	not tested	+	not tested	+	\checkmark		
Cytosine Arabinoside	+	not tested	+	not tested	+	\checkmark		
Methyl Methanesulfonate	+	not tested	+	not tested	+	\checkmark		

Good concordance between standard tube and 96-Well formats



In Vitro MN: Standard v 96-Well Scoring



16 Genetic Toxicology Screening October 2018

 Good concordance between standard tube and 96-Well formats



In Vitro MN Screen: Manual v Metafer Analysis

Manual Versus Metafer: Mitomycin C Micronucleus Data 15 MMC: 27+27 hour -S-9 14 2% 13 12 Expt 2: Metafer Expt 1: Manual Expt 2: Manual 11 Expt 1: Metafer 10 2% 9 169 %MNBN Cells 8 8% Historical control Upper range 7 6 13% 13% 5 4 3 2 0 0.0000 0.0125 0.0250 0.0000 0.0125 0.0250 0.0000 0.0125 0.0250 0.0000 0.0125 0.0250 Concentration (µg/mL)

Manual versus Semi-Automated Metafer Analysis







Metafer MSearch gallery showing MN analysis.



In Vitro MN Screen: Pros / Cons

- 96-well format generally show good concordance with standard tube based assay
 - Outcome (positive / negative)
 - Good concentration concordance
- Significantly less test article used
- Use of (semi-)automation reduces turn around times
- Fewer cells scored
- May not evaluate all three treatment conditions





Conclusion

- Early Screening allows earlier identification of genotoxic compounds
 - Saves valuable time and resource
- Miniaturised screens require significantly less test article
- Miniaturised screens have good concordance with corresponding regulatory assays

WHAT ARE THE NEXT STEPS FOR SCREENING...

- Future developments/techniques may improve turnaround time and provide additional relevant information with limited compound
- Automated micronucleus analysis
 - Automated image based platforms
 - Flow cytometry
 - Imaging flow cytometry (e.g. ImageStream)
- ► Additional/multiple endpoints e.g. MultiFlowTM
 - Aneugen, Clastogen or Non-genotoxic
 - Mode of Action



19 Genetic Toxicology Screening October 2018

About Covance / Thank You

Covance Inc., headquartered in Princeton, NJ, USA, is the drug development business of Laboratory Corporation of America Holdings (LabCorp). COVANCE is a registered trademark and the marketing name for Covance Inc. and its subsidiaries around the world.

